Experimental Bladder Cancer Models for Animals

被引:0
|
作者
Kosan, Murat [1 ]
Mungan, Aydin [2 ]
机构
[1] Baskent Univ, Tip Fak, Urol Anabilim Dali, Konya, Turkey
[2] Bulent Ecevit Univ, Tip Fak, Urol Anabilim Dali, Zonguldak, Turkey
来源
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY | 2015年 / 14卷 / 01期
关键词
Bladder cancer; transitional cell carcinoma; experimental animal models;
D O I
10.4274/uob.283
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transitional cell carcinoma (TCC) is the most common malignancy of the genitourinary tract and TCC models are being developed over the past decades. Experimental models are needed so that more effective treatments can be developed in preclinical evaluation. Even if, in vitro models are useful for initial development and evaluation of therapeutic agents and modalities, adequate animal models are still essential in the preclinical development of new effective and safe therapies. A great variety of ex vivo and in vivo models has been described in the literature. Chemical carcinogens are most commonly used to induce bladder cancer. Cell culture techniques are also widely used to study different oncological processes. To test potential new drugs in a preclinical setting, a clinically relevant orthotopic bladder tumor model is highly desirable. The aim of this review article was the assessment of different animal models available for the study of bladder carcinogenesis.
引用
收藏
页码:29 / 32
页数:4
相关论文
共 50 条
  • [21] Development of Subtype-specific Models of Bladder Cancer
    Saito, Ryoichi
    Matsumoto, Keiyu
    Murakami, Kaoru
    Kita, Yuki
    Akamatsu, Shusuke
    Kobayashi, Takashi
    Yamasaki, Toshinari
    Inoue, Takahiro
    Ogawa, Osamu
    CANCER SCIENCE, 2018, 109 : 166 - 166
  • [22] Lymphatic vessel density and function in experimental bladder cancer
    Marcia R Saban
    Rheal Towner
    Nataliya Smith
    Andrew Abbott
    Michal Neeman
    Carole A Davis
    Cindy Simpson
    Julie Maier
    Sylvie Mémet
    Xue-Ru Wu
    Ricardo Saban
    BMC Cancer, 7
  • [23] Disparities in bladder cancer
    Jacobs, Bruce L.
    Montgomery, Jeffrey S.
    Zhang, Yun
    Skolarus, Ted A.
    Weizer, Alon Z.
    Hollenbeck, Brent K.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (01) : 81 - 88
  • [24] Immunotherapy for bladder cancer
    Kamat A.M.
    Lamm D.L.
    Current Urology Reports, 2001, 2 (1) : 62 - 69
  • [25] Bladder cancer in women
    Baniel J.
    International Urogynecology Journal, 1999, 10 (6) : 399 - 404
  • [26] Selenoproteins in bladder cancer
    Reszka, Edyta
    CLINICA CHIMICA ACTA, 2012, 413 (9-10) : 847 - 854
  • [27] Radiochemotherapy for Bladder Cancer
    Ott, O. J.
    Roedel, C.
    Weiss, C.
    Wittlinger, M.
    Krause, F. St.
    Dunst, J.
    Fietkau, R.
    Sauer, R.
    CLINICAL ONCOLOGY, 2009, 21 (07) : 557 - 565
  • [28] Immunotherapy in Bladder Cancer
    Vasekar, Monali
    Degraff, David
    Joshi, Monika
    CURRENT MOLECULAR PHARMACOLOGY, 2016, 9 (03) : 242 - 251
  • [29] Biomarkers in bladder cancer
    Bryan, Richard T.
    Zeegers, Maurice P.
    James, Nicholas D.
    Wallace, D. Michael A.
    Cheng, Kar Keung
    BJU INTERNATIONAL, 2010, 105 (05) : 608 - 613
  • [30] Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer
    Bostroem, Peter J.
    Alkhateeb, Sultan
    Trottier, Greg
    Athanasopoulos, Paul Z.
    Mirtti, Tuomas
    Kortekangas, Hannes
    Laato, Matti
    van Rhijn, Bas
    van der Kwast, Theo
    Fleshner, Neil E.
    Jewett, Michael A.
    Finelli, Antonio
    Zlotta, Alexandre R.
    BJU INTERNATIONAL, 2012, 109 (01) : 70 - 76